Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients.
FACT-G
GP5
Health-related quality of life
Oncology
Psychometric validity
Symptom bother
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
28
04
2021
accepted:
31
12
2021
pubmed:
16
1
2022
medline:
23
2
2022
entrez:
15
1
2022
Statut:
ppublish
Résumé
With higher efficacy of cancer therapies, the numbers and types of side effects experienced by patients have also increased, evidencing a need for brief assessments of side effect bother. The Functional Assessment of Cancer Therapy-General (FACT-G) includes the item "I am bothered by side effects of treatment" (GP5). This study aimed to confirm GP5's validity in a large, diverse, real-world patient sample. Real-world data were drawn from 10 Adelphi Disease Specific Programmes (DSP™) conducted between 2015 and 2019 in France, Germany, Italy, Spain, the UK and the USA, covering 10 cancer sites. We examined correlations between GP5 responses and varied measures of patient-reported global health and the number of side effects experienced. We explored whether more advanced patients and those with worse Eastern Cooperative Oncology Group Performance Status Rating (ECOG PSR) reported greater side effect bother. Finally, we conducted differential item functioning (DIF) assessment using the Mantel-Haenszel approach. The sample included 6755 advanced cancer patients. GP5 responses were distributed similarly across most cancer sites. A moderate, negative correlation (r GP5 exhibited evidence of validity across cancer sites and countries and appeared to measure the same construct across these countries. GP5 has significant promise as a summary indicator of side effect bother.
Identifiants
pubmed: 35031830
doi: 10.1007/s00520-022-06802-3
pii: 10.1007/s00520-022-06802-3
pmc: PMC8857159
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3613-3623Informations de copyright
© 2022. The Author(s).
Références
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387. https://doi.org/10.1016/j.ejca.2018.07.005
doi: 10.1016/j.ejca.2018.07.005
pubmed: 30100160
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol 15(1):23–34. https://doi.org/10.1016/S1470-2045(13)70546-1
doi: 10.1016/S1470-2045(13)70546-1
pubmed: 24314615
Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, Rowden D (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118(S8):2207–2216. https://doi.org/10.1002/cncr.27469
doi: 10.1002/cncr.27469
pubmed: 22488695
Savard J, Ivers H, Savard M-H, Morin CM (2015) Cancer treatments and their side effects are associated with aggravation of insomnia: results of a longitudinal study. Cancer 121(10):1703–1711. https://doi.org/10.1002/cncr.29244
doi: 10.1002/cncr.29244
pubmed: 25677509
Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, Carlsen E, Tveit KM (2010) Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76(4):1005–1011. https://doi.org/10.1016/j.ijrobp.2009.03.010
doi: 10.1016/j.ijrobp.2009.03.010
pubmed: 19540058
Bertrand A, Kostine M, Barnetche T, Truchetet M-E, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13(1):211. https://doi.org/10.1186/s12916-015-0455-8
doi: 10.1186/s12916-015-0455-8
pubmed: 26337719
pmcid: 4559965
Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934. https://doi.org/10.1016/j.ctrv.2012.05.002
doi: 10.1016/j.ctrv.2012.05.002
pubmed: 22658913
Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M (2010) It’s not over when it’s over: long-term symptoms in cancer survivors—a systematic review. Int J Psychiat Med 40(2):163–181. https://doi.org/10.2190/PM.40.2.c
doi: 10.2190/PM.40.2.c
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261–2269. https://doi.org/10.1007/s00520-014-2255-7
doi: 10.1007/s00520-014-2255-7
pubmed: 24789421
Jansen L, Koch L, Brenner H, Arndt V (2010) Quality of life among long-term (⩾5years) colorectal cancer survivors – systematic review. Eur J Cancer 46(16):2879–2888. https://doi.org/10.1016/j.ejca.2010.06.010
doi: 10.1016/j.ejca.2010.06.010
pubmed: 20605090
Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. JNCI J Nat Cancer Inst 104(5):386–405. https://doi.org/10.1093/jnci/djr541
doi: 10.1093/jnci/djr541
pubmed: 22271773
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O’Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ (2018) Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop. Value Health 21(6):742–747. https://doi.org/10.1016/j.jval.2017.09.009
doi: 10.1016/j.jval.2017.09.009
pubmed: 29909880
Kim J, Singh H, Ayalew K, Borror K, Campbell M, Johnson LL, Karesh A, Khin NA, Less JR, Menikoff J, Minasian L, Mitchell SA, Papadopoulos EJ, Piekarz RL, Prohaska KA, Thompson S, Sridhara R, Pazdur R, Kluetz PG (2018) Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections. Clin Cancer Res 24(8):1780–1784. https://doi.org/10.1158/1078-0432.CCR-17-2555
doi: 10.1158/1078-0432.CCR-17-2555
pubmed: 29237718
Basch E, Campbell A, Hudgens S, Jones L, King-Kallimanis B, Kluetz P, O'connor D, Rosen O (2020) Broadening the definition of tolerability in cancer clinical trials to capture the patient experience. Friends of Cancer Research, Friends of Cancer Research
Pearman TP, Beaumont JL, Mroczek D, O’Connor M, Cella D (2018) Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer 124(5):991–997. https://doi.org/10.1002/cncr.31133
doi: 10.1002/cncr.31133
pubmed: 29131323
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579. https://doi.org/10.1200/JCO.1993.11.3.570
doi: 10.1200/JCO.1993.11.3.570
pubmed: 8445433
Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M (2004) Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study1 1The members of the Chiba Prostate Study Group are listed in the Appendix. Urology 64(2):341–345. https://doi.org/10.1016/j.urology.2004.03.032
doi: 10.1016/j.urology.2004.03.032
pubmed: 15302491
Cella D, Wang M, Wagner L, Miller K (2011) Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat 130(3):855–861. https://doi.org/10.1007/s10549-011-1725-6
doi: 10.1007/s10549-011-1725-6
pubmed: 21874312
pmcid: 3684040
Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ (2010) Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis. Br J Cancer 102(4):658–664. https://doi.org/10.1038/sj.bjc.6605552
doi: 10.1038/sj.bjc.6605552
pubmed: 20104222
pmcid: 2837567
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016) Real-world evidence - what is it and what can it tell us? N Engl J Med 375(23):2293–2297. https://doi.org/10.1056/NEJMsb1609216
doi: 10.1056/NEJMsb1609216
pubmed: 27959688
Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD (2007) Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value in Health 10(5):326–335. https://doi.org/10.1111/j.1524-4733.2007.00186.x
doi: 10.1111/j.1524-4733.2007.00186.x
pubmed: 17888097
Khozin S, Blumenthal GM, Pazdur R (2017) Real-world data for clinical evidence generation in oncology. JNCI J Nat Cancer Inst 109 (11). https://doi.org/10.1093/jnci/djx187
Anderson P, Benford M, Harris N, Karavali M, Piercy J (2008) Real-world physician and patient behaviour across countries: disease-specific programmes–a means to understand. Curr Med Res Opin 24(11):3063–3072
doi: 10.1185/03007990802457040
Babineaux S, Curtis B, Holbrook T, Milligan G, Piercy J (2016) Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open 6 (8)
Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, Benford M (2016) Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metabol Syndr Obes Targets Ther 9:371
doi: 10.2147/DMSO.S120101
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655
doi: 10.1097/00000421-198212000-00014
SAS Institute I (2013) Base SAS
Fayers PM, Machin D (2016) Quality of life: the assessment, analysis and interpretation of patient‐reported outcomes. John Wiley & Sons, Ltd, West Sussex, UK
Wright KD, Oshima TC (2015) An effect size measure for Raju’s differential functioning for items and tests. Educ Psychol Meas 75(2):338–358. https://doi.org/10.1177/0013164414532944
doi: 10.1177/0013164414532944
pubmed: 29795824
Fumimoto H, Kobayashi K, Chang C-H, Eremenco S, Fujiki Y, Uemura S, Ohashi Y, Kudoh S (2001) Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 10(8):701–709. https://doi.org/10.1023/a:1013851216181
doi: 10.1023/a:1013851216181
pubmed: 11871591
Conroy T, Mercier M, Bonneterre J, Luporsi E, Lefebvre JL, Lapeyre M, Puyraveau M, Schraub S (2004) French version of FACT-G: validation and comparison with other cancer-specific instruments. Eur J Cancer 40(15):2243–2252. https://doi.org/10.1016/j.ejca.2004.06.010
doi: 10.1016/j.ejca.2004.06.010
pubmed: 15454249
Peipert JD, Cella D (2019) Bifactor analysis confirmation of the factorial structure of the Functional Assessment of Cancer Therapy-General (FACT-G). Psychooncology 28(5):1149–1152. https://doi.org/10.1002/pon.5062
doi: 10.1002/pon.5062
pubmed: 30883962
Pearman T, Yanez B, Peipert J, Wortman K, Beaumont J, Cella D (2014) Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer 120(18):2902–2909. https://doi.org/10.1002/cncr.28758
doi: 10.1002/cncr.28758
pubmed: 24853866
Wagner LI, Zhao F, Goss PE, Chapman J-AW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Res Treat 169(3):537–548. https://doi.org/10.1007/s10549-018-4713-2
doi: 10.1007/s10549-018-4713-2
pubmed: 29455298
pmcid: 6092930
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St. Germain D, O’Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JNCI Journal of the National Cancer Institute 106(9):dju244–dju244. https://doi.org/10.1093/jnci/dju244
doi: 10.1093/jnci/dju244
pubmed: 25265940
pmcid: 4200059
Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O’Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E, on behalf of the National Cancer Institute PROCSG (2015) Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059. https://doi.org/10.1001/jamaoncol.2015.2639
doi: 10.1001/jamaoncol.2015.2639
pubmed: 26270597
pmcid: 4857599
Garcia SF, Rosenbloom SK, Beaumont JL, Merkel D, Von Roenn JH, Rao D, Cella D (2012) Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). Value Health 15(1):183–190. https://doi.org/10.1016/j.jval.2011.08.1739
doi: 10.1016/j.jval.2011.08.1739
pubmed: 22264987
Butt Z, Parikh ND, Beaumont JL, Rosenbloom SK, Syrjala KL, Abernethy AP, Benson AB 3rd, Cella D (2012) Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). Cancer 118(23):5997–6004. https://doi.org/10.1002/cncr.27588
doi: 10.1002/cncr.27588
pubmed: 22605658
Yount S, Beaumont J, Rosenbloom S, Cella D, Patel J, Hensing T, Jacobsen PB, Syrjala K, Abernethy AP (2012) A brief symptom index for advanced lung cancer. Clin Lung Cancer 13(1):14–23. https://doi.org/10.1016/j.cllc.2011.03.033
doi: 10.1016/j.cllc.2011.03.033
pubmed: 21729652
Hlubocky FJ, Webster K, Beaumont J, Cashy J, Paul D, Abernethy A, Syrjala KL, Von Roenn J, Cella D (2013) A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index. Leuk Lymphoma 54(9):1942–1946. https://doi.org/10.3109/10428194.2012.762977
doi: 10.3109/10428194.2012.762977
pubmed: 23320888
pmcid: 5889924
Victorson DE, Beaumont JL, Rosenbloom SK, Shevrin D, Cella D (2011) Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psychooncology 20(9):977–983. https://doi.org/10.1002/pon.1817
doi: 10.1002/pon.1817
pubmed: 20661866
Cella D, Rosenbloom SK, Beaumont J, Yount S, Paul D, Hamptond D, Abernethy A, Jacobsen PB, Syrjala K, Von Roenn J (2011) Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. JNCCN Volume 9 Number 3